Physician profile
Thi Khuc
NPI 1538692652
$5,928.73
in general payments reported to CMS, 2019-2025
28 companies · $1,414 in 2025
The $1,414 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $449 · 2022: $938 · 2023: $865 · 2024: $2,263 · 2025: $1,414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,381 · Education: $161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,380.65 |
| Education | $160.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,370.66 | 2021-2025 | |
| Janssen Biotech, INC. | $536.89 | 2023-2025 | Stelara, Tremfya, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $519.86 | 2022-2025 | Xifaxan, Trulance, Plenvu |
| Gilead Sciences, INC. | $514.90 | 2022-2024 | Vemlidy |
| Pfizer INC. | $481.54 | 2023-2025 | |
| Intercept Pharmaceuticals, INC. | $375.35 | 2021-2025 | Ocaliva |
| Digestive Care, INC. | $290.77 | 2021-2022 | |
| Qol Medical, LLC | $270.39 | 2023-2024 | Sucraid, Sucraid |
| Celgene Corporation | $208.68 | 2023-2024 | Zeposia |
| Genzyme Corporation | $203.06 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $187.23 | 2023-2025 | Dupixent |
| Medtronic, INC. | $175.43 | 2022-2025 | Pillcam, Gi Genius |
| E.R. Squibb & Sons, L.L.C. | $126.87 | 2023 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $125.21 | 2022-2025 | Entyvio |
| Phathom Pharmaceuticals, INC. | $103.42 | 2024-2025 | Voquezna |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $87.00 | 2023-2024 | Ibsrela |
| Celltrion USA INC. | $85.51 | 2024-2025 | Vegzelma |
| Boston Scientific Corporation | $36.35 | 2022 | |
| Exelixis INC. | $34.47 | 2022 | |
| Alnylam Pharmaceuticals INC. | $32.57 | 2022-2023 | Givlaari |
| Aimmune Therapeutics, INC. | $30.08 | 2025 | Zenpep |
| Madrigal Pharmaceuticals | $30.08 | 2025 | Rezdiffra |
| Eisai INC. | $23.21 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $19.84 | 2025 | |
| Lilly USA, LLC | $15.40 | 2023 | |
| Merck Sharp & Dohme LLC | $15.07 | 2024 | Dificid |
| Braintree Laboratories, INC. | $14.58 | 2023 | Suflave, Sutab |
| Micro-Tech Endoscopy USA, INC. | $14.31 | 2023 | Lesionhunter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thi Khuc listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.